Alzheimer's groups speak out against proposed Medicare restrictions on controversial drug
The U.S. Food and Drug Administration's accelerated approval of an Alzheimer's drug known as aducanumab, or Aduhelm, drew major controversy. But the drug brought hope for many patients.
Now the Centers for Medicare and Medicaid Services is proposing that Medicare only cover the drug for individuals enrolled in clinical trials. Alzheimer’s advocacy groups are speaking out against the proposal. CMS officials have said they plan to announce a final decision by April 11.
Joining Cincinnati Edition to discuss Aduhelm are Ohio State University Wexner Medical Center Center for Cognitive and Memory Disorders Director Douglas Scharre, MD; Cincinnati resident Shelley Goshorn, whose partner is in a clinical trial for Aduhelm; The Alzheimer's Association Greater Greater Cincinnati Chapter Executive Director Annemarie Barnett; and Johns Hopkins Bloomberg School of Public HealthProfessor of Epidemiology Caleb Alexander, MD, who was a member of the FDA advisory panel that reviewed two clinical trials related to the drug.
Listen to Cincinnati Edition live at noon M-F. Audio for this segment will be uploaded after 4 p.m. ET.
Never miss an episode by subscribing to our podcast: